Search clinical trials for: MDX1106-02

Total 346 results

ViaCyte

Completed

A Safety and Tolerability Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Canada
Nobelpharma

Completed

Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan.

Wilson's Disease
Nobelpharma

Completed

Dose Adjustment Study of NPC-02 in Patients With Zinc Deficiency

Zinc Deficiency

Japan
Nu Eyne Co., Ltd.

Completed

The Evaluation of the Transcutaneous Electrical Stimulation Medical Device's Safety and Effectiveness in Treating the Patients With Dry Eye Disease

Dry Eye Disease

Korea, Republic of
Shanghai General Hospital, Shanghai Jiao Tong University...
NanoMab Technology (UK) Limited

Recruiting

HER2 Expression Detection and Radionuclide Therapy in Breast Cancer Using 99mTc/188Re Labeled Single Domain Antibody

Breast Cancer | Radiotoxicity

China
Providence Health & Services
Providence Cancer Center, Earle A. Chiles Research Institute; Galectin Therapeutics...

Completed

Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma

Metastatic Melanoma

United States
University of British Columbia

Recruiting

Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma

Transitional Cell Cancer of the Renal Pelvis and Ureter | Urothelial Carcinoma of the Renal Pelvis and Ureter

Canada
Nobelpharma

Completed

A Randomized, Double-Blind, Placebo Controlled Study of NPC-02 in Patients With Zinc Deficiency

Zinc Deficiency

Japan
Mannkind Corporation

Terminated

Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma

Stage IV Melanoma | Stage III Melanoma

United States
Dendreon

Terminated

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Urothelial Carcinoma

United States
Mesoestetic Pharma Group S.L.
Opera CRO, a TIGERMED Group Company

Completed

Pilot Trial to Assess the Performance and Tolerance of mRDX-02-17 Dermal Filler in the Facial Rejuvenation

Facial Rejuvenation

Romania
Biointegrator LLC

Terminated

Open-label Study of Safety, Tolerability and Pharmacokinetics of Multiple Doses of BI-CON-02 in Patients With HER2-positive Metastatic Breast Cancer, Previously Treated With Trastuzumab

Metastatic Breast Cancer

Russian Federation
Mannkind Corporation

Completed

Vaccine Therapy in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
Oyster Point Pharma, Inc.

Completed

Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)

Dry Eye Disease

United States
Barry Miskin, MD
Jupiter Medical Center

Completed

Hyperbaric Treatment of Traumatic Brain Injury (TBI) (TBI)

Traumatic Brain Injury

United States
Dr. Reddy's Laboratories Limited
Duke Clinical Research Institute

Completed

DFA-02 in Patients Undergoing Colorectal Surgery

Surgical Site Infection

United States
Dan Zandberg
Bristol-Myers Squibb

Active, not recruiting

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Squamous Cell Carcinoma of the Head and Neck

United States
Sixth Affiliated Hospital, Sun Yat-sen University

Unknown

The Role of MSC in the Treatment of Fistulas in Patients With Perianal Crohn's Disease

Fistula | Crohn's Disease
EdiGene (GuangZhou) Inc.
The First Affiliated Hospital of Henan University of Science and Technology

Active, not recruiting

A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)

Relapsed or Refractory B-cell Malignancy(NHL/ALL)

China
Parion Sciences

Completed

A Safety and Efficacy Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome

Xerostomia | Dry Mouth Associated With Sjogren's Syndrome

United States
CNBG-Virogin Biotech (Shanghai) Ltd.
Shulan (Hangzhou) Hospital

Recruiting

A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

SARS-CoV-2 Infection

China
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Recruiting

NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States
Eloxx Pharmaceuticals, Inc.

Terminated

A Phase 2 Study of ELX-02 in Patients With Nephropathic Cystinosis

Genetic Disease | Cystinosis | Nonsense Mutation

Canada
University of Texas Southwestern Medical Center

Withdrawn

Nivolumab Based Immunotherapy for Treatment of High Grade Cervical Dysplasia

Cervix Uteri--Diseases
Eloxx Pharmaceuticals, Inc.

Recruiting

A Study of ELX-02 in Patients With Alport Syndrome

Alport Syndrome

United Kingdom, Australia
Eloxx Pharmaceuticals, Inc.
Syneos Health

Completed

A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02

Impaired Renal Function

United States
Galectin Therapeutics Inc.

Completed

Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis (NASH-FX)

Nonalcoholic Steatohepatitis

United States
Axsome Therapeutics, Inc.

Unknown

A Study to Assess the Efficacy and Safety of AXS-02 in Subjects With Knee OA Associated With Bone Marrow Lesions (COAST-1)

Osteoarthritis, Knee

United States, Australia
Jazz Pharmaceuticals

Completed

Study to Compare the Safety and Tolerability of Sativex® in Patients With Cancer Related Pain

Pain | Cancer

United Kingdom
Prometheus Laboratories
Syneos Health; Nestlé Health Science Spain

Terminated

A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC) (PROTECT-3)

Ulcerative Colitis

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Recruiting

Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

Sarcoma | Solid Tumor, Adult | Solid Tumor, Childhood

United States
Vedic Lifesciences Pvt. Ltd.

Recruiting

A Study to Evaluate Efficacy of Different Natural Ingredients in Improving Gut Health in Adults With Leaky Gut.

Gut Health

India
University of Rochester
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Completed

NIR Fluorescence Imaging of Lymphatic Transport Using ICG (NIR-ICG)

Rheumatoid Arthritis

United States
TAK-Circulator Co.

Completed

The Safety and Pharmacokinetics Study of TAKC-02 Inhalation Solution in Healthy Adult Males.

Healthy Volunteer

Japan
AVROBIO

Withdrawn

An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3

Gaucher Disease, Type 3
Afexa Life Sciences Inc

Terminated

GLU-xx Formulations in Individuals With Impaired Glucose Tolerance

Impaired Glucose Tolerance

United States
Mannkind Corporation

Completed

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.

Advanced Melanoma | Stage III and IV Melanoma

United States
University of Colorado, Denver
Bristol-Myers Squibb

Recruiting

Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers

Tobacco Smoking | Bronchial Dysplasia | History of Non-Small Cell Lung Cancer | History of Head and Neck Cancer

United States
University of Rochester
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Recruiting

Imaging of Lymphatic Vessels in People With Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

United States
Galectin Therapeutics Inc.

Completed

A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

Hepatic Impairment

United States
Eloxx Pharmaceuticals, Inc.
SGS Life Sciences, a division of SGS Belgium NV

Completed

Phase 1 Study of ELX-02 in Healthy Adult Subjects

Genetic Disease | Nonsense Mutation

Belgium
Vertex Pharmaceuticals Incorporated

Recruiting

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

Diabetes Mellitus, Type 1 | Impaired Hypoglycemic Awareness | Severe Hypoglycemia

United States, Norway, Italy, Canada, France, United Kingdom, Switzerland, Netherlands, Germany
MediWound Ltd

Completed

A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers

Venous Leg Ulcer

United States, Switzerland
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (PROSPER)

Metastatic Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Unclassified Renal Cell Carcinoma | Stage II Renal Cell Cancer AJCC v7

United States, Canada, Israel
Galectin Therapeutics Inc.
Dr. Naga Chalasani, MD, Indiana University; Dr. Stephen A. Harrison, MD, Brooke...

Completed

Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis (NASH-CX)

Hypertension, Portal

United States
Shanghai General Hospital, Shanghai Jiao Tong University...
NanoMab Technology (UK) Limited

Completed

HER2 Expression Detection in Breast Cancer Using 99mTc-NM-02

Breast Cancer

China
University of Chicago

Completed

A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma

Mesothelioma | Peritoneal Mesothelioma

United States
University of Michigan Rogel Cancer Center
Bristol-Myers Squibb

Completed

Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

Peripheral T Cell Lymphoma

United States
MRC/UVRI and LSHTM Uganda Research Unit

Recruiting

Safety and Immunogenicity of LNP-nCOV saRNA-02 Vaccine Against SARS-CoV-2, the Causative Agent of COVID-19 (COVAC-Uganda)

COVID-19

Uganda
National Institute of Allergy and Infectious Diseases...

Completed

H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo...

Influenza

United States

Search clinical trials for: MDX1106-02

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations